Table I
Primers used in this study.
| Primer | Primer sequence (5’–3’) | Target gene | References |
|---|---|---|---|
| intF | CCAAGCTCTCGGGTAACATC | intI1 | Wang et al. 2023 |
| P2R | CCCGAGGCATAGACTGTA | ||
| 5CS | GGCATCCAAGCAGCAAG | variable region | Wang et al. 2023 |
| 3CS | AAGCAGACTTGACCTGA | ||
| AACF | ATCTCATATCGTCGAGTGG | aac(6’)-Ib | Wang et al. 2023 |
| AACR | TGCGTGTTCGCTCGAATGC | ||
| AADAF | GCAGCGCAATGACATTCTTG | aadA1 | Wang et al. 2023 |
| AADAR | ATCCTTCGGCGCGATTTTG | ||
| CATF | TTACTCTGGCTACTATCAC | catB8 | Wang et al. 2023 |
| CATR | TGATGGCATAAGGCTCTAC | ||
| KPC-F | CGTCTAGTTCTGCTGTCTTG | blaKPC | Wang et al. 2023 |
| KPC-R | CTTGTCATCCTTGTTAGGCG | ||
| VIM-F | GATGGTGTTTGGTCGCATA | blaVIM | Wang et al.2023 |
| VIM-R | CGAATGCGCAGCACCAG | ||
| NDM-F | GGTTTGGCGATCTGGTTTTC | blaNDM | Wang et al. 2023 |
| NDM-R | CGGAATGGCTCATCACGATC | ||
| OXA-23-like-F | CCGTCGTTTACGACATTCA | blaOXA-23-like | Wang et al.2023 |
| OXA-23-like-R | AAAGAGCGCATTGCTTTGAT | ||
| IMP-F | GGAATAGAGTGGCTTAAYTCTC | blaIMP | Wang et al.2023 |
| IMP-R | GGTTTAAYAAAACAACCACC | ||
| bfmS-F | ATATATGCGGGGCTGGTAATTC | bfms | Cai et al. 2017 |
| bfmS-R | ATGCAGGTGCTTTTTTATTGGT | ||
| cusE-F | ATGCATGTTCTCTGGACTGATGTTGAC | cusE | Cai et al. 2017 |
| cusE-R | CGACTTGTACCGTGACCGTATCTTGATAAG | ||
| bap-F | CGTTTCCTGGGTCTGATGTATT | bap | Cai et al. 2017 |
| bap-R | GTTATTGAAGGCTTCTTTAGTG | ||
| abal-F | GTGGCTCAAGACAGAGAATC | abal | Wang and Ye 2021 |
| abal-R | TCAATCATCATTGGTGGACC | This study |

Fig. 1.
Clinical ward distribution of CRAB and CSAB isolates.

Fig. 2.
Clinical specimen type distribution of CRAB and CSAB isolates.
Table II
Resistance rates of CRAB and CSAB isolates to commonly used antibiotics.
| Antibiotics | CRAB (n = 219) | CSAB (n = 50) | p | ||
|---|---|---|---|---|---|
| No. | Rate (%) | No. | Rate (%) | ||
| CAZ | 218 | 99.54 | 6 | 12.00 | 0.000* |
| CIP | 217 | 99.09 | 6 | 12.00 | 0.000* |
| TOB | 206 | 94.06 | 6 | 12.00 | 0.000* |
| DOX | 216 | 98.63 | 6 | 12.00 | 0.000* |
| SXT | 166 | 75.80 | 8 | 16.00 | 0.000* |
| LVX | 175 | 79.91 | 5 | 10.00 | 0.000* |
| AMK | 131 | 59.82 | 6 | 12.00 | 1.000 |
| FEP | 169 | 77.17 | 6 | 12.00 | 0.384 |
| MNO | 78 | 35.62 | 2 | 4.00 | 0.000* |
| TGC | 11 | 5.02 | 0 | 0.00 | 0.226 |
| COL | 3 | 1.37 | 0 | 0.00 | 1.000 |
1 CAZ – ceftazidime, CIP – ciprofloxacin, TOB – tobramycin, DOX – doxycycline, SXT – trimethoprim/sulfamethoxazole, LVX – levofloxacin, AMK – amikacin, FEP – cefepime, MNO minocycline, TGC – tigecycline, COL – colistin, CRAB – carbapenem-resistant Acinetobacter baumannii, CSAB – carbapenem-sensitive A. baumannii
n – the number of strains in the group
Table III
Virulence- and resistance-gene-carrying status of CRAB and CSAB.
Table IV
Correlations between virulence genes and antibiotic resistance in 219 CRAB isolates.
| Antibiotics | abal | bfmS | cusE | bap | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| + (n = 204) | – (n = 15) | p | + (n = 140) | – (n = 79) | p | + (n = 170) | – (n = 49) | p | + (n = 193) | – (n = 26) | p | |
| MNO | 72 | 6 | 0.782 | 47 | 31 | 0.4 | 59 | 19 | 0.6 | 68 | 10 | 0.747 |
| DOX | 201 | 15 | 1 | 139 | 77 | 0.296 | 168 | 48 | 0.534 | 191 | 25 | 0.317 |
| SXT | 154 | 12 | 1 | 98 | 68 | 0.008* | 124 | 42 | 0.066 | 145 | 21 | 0.528 |
| CIP | 202 | 15 | 1 | 139 | 78 | 1 | 168 | 49 | 1 | 192 | 25 | 0.224 |
| LVX | 163 | 12 | 1 | 109 | 66 | 0.313 | 141 | 34 | 0.037* | 152 | 23 | 0.246 |
| TOB | 191 | 15 | 0.607 | 129 | 77 | 0.142 | 161 | 45 | 0.494 | 185 | 21 | 0.011* |
| AMK | 125 | 6 | 0.105 | 79 | 52 | 0.173 | 96 | 35 | 0.06 | 119 | 12 | 0.13 |
| TGC | 11 | 0 | 1 | 9 | 2 | 0.335 | 9 | 2 | 1 | 11 | 0 | 0.369 |
| CAZ | 203 | 15 | 1 | 139 | 79 | 1 | 169 | 49 | 1 | 192 | 26 | 1 |
| FEP | 156 | 13 | 0.74 | 112 | 57 | 0.184 | 141 | 28 | 0* | 148 | 21 | 0.641 |
| COL | 3 | 0 | 1 | 2 | 1 | 1 | 2 | 1 | 0.534 | 2 | 1 | 0.317 |
1 CAZ – ceftazidime, CIP – ciprofloxacin, TOB – tobramycin, DOX – doxycycline, SXT – trimethoprim/sulfamethoxazole, LVX – levofloxacin, AMK – amikacin, FEP – cefepime, MNO minocycline, TGC – tigecycline, COL – colistin, CRAB – carbapenem-resistant Acinetobacter baumannii
n – the number of strains in the group
Table V
Correlation between class 1 integron and antibiotic resistant rates in 219 CRAB isolates.
| Antibiotics | intI1(+) (n = 75) | intI1(−) (n = 144) | p | ||
|---|---|---|---|---|---|
| No. | Rate (%) | No. | Rate (%) | ||
| CAZ | 75 | 100 | 143 | 99.31 | 1.000 |
| CIP | 75 | 100 | 142 | 98.61 | 0.548 |
| TOB | 75 | 100 | 132 | 91.67 | 0.009* |
| DOX | 74 | 98.67 | 142 | 98.61 | 1.000 |
| SXT | 73 | 97.33 | 93 | 64.58 | 0.000* |
| LVX | 62 | 82.67 | 113 | 78.47 | 0.462 |
| AMK | 58 | 77.33 | 78 | 54.17 | 0.001* |
| FEP | 44 | 58.67 | 125 | 86.81 | 0.000* |
| MNO | 36 | 48 | 42 | 29.17 | 0.006* |
| TGC | 1 | 1.33 | 10 | 6.94 | 0.103 |
| COL | 1 | 1.33 | 2 | 1.39 | 1.000 |
1 CAZ – ceftazidime, CIP – ciprofloxacin, TOB – tobramycin, DOX – doxycycline, SXT – trimethoprim/sulfamethoxazole, LVX – levofloxacin, AMK – amikacin, FEP – cefepime, MNO minocycline, TGC – tigecycline, COL – colistin CRAB – carbapenem-resistant Acinetobacter baumannii
n – the number of strains in the group